Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
400.00    0.00 (0.00%)
Bid:
395.00
Ask:
405.00
Spread: 10.00 (2.532%)
Market Cap: £191.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

China Licence received

12 May 2011 08:00

RNS Number : 4596G
Tristel PLC
12 May 2011
Β 

ο»Ώ

Tristel plc

("Tristel" or "the Company")

AIM: TSTL

Β 

Licence to sell Stella decontamination system received in China

Β 

Tristel plc, the manufacturer of infection control, contamination control and hygiene products, announces that it has received the administrative licence that will enable the use of its Stella decontamination system in China.

Β 

Stella is a sophisticated micro-processor controlled tray in which medical instruments are immersed in Tristel's chlorine dioxide disinfectant. Hospitals can employ Stella at a fraction of the capital and running cost of the endoscope washers that are widely used as the only alternative to the age-old practice of placing instruments in a sink or simple plastic container.

Β 

Stella is particularly relevant to hospital departments such as urology, gynaecology, respiratory, cardiology and GI physiology. It deliberately cannot be used with the large flexible endoscopic instruments that are the focus of most of Tristel's competitors.

Β 

Tristel received regulatory approval for Stella last Autumn and the receipt of the licence enables its use by hospitals. The Company's China subsidiary, Shanghai Stella Medical Equipment Co. Ltd., has already appointed six distributors for the Stella system. These distributors purchased 30 Stella units between June and December 2010 for training and evaluation purposes. The Company has established its own sales force to sell directly in the Shanghai metropolitan area.

Β 

Outside of China, Tristel has sold 63 Stella units in the United Kingdom, Belgium, Spain, Ireland, Italy, Dubai, New Zealand and Germany. In a clinical study recently concluded Stella has been subjected to a randomised single-blind comparison with the world's leading brand of instrument disinfectant used in one of the most widely used endoscope washers. Stella's efficacy has been shown to be the equivalent of the process to which it was compared, but it produced vast savings in cost and process time. The study is anticipated to be published later this year.

Β 

Paul Swinney, Chief Executive of Tristel, said: "We have been eagerly awaiting receipt of this licence for many months because Stella sales in China had been forecast to be a major contributor to our top-line growth this year. Our team in Shanghai will now make every effort to close as much business as possible although our year end is approaching fast. We are confident that the market in China will play an important part in next year's business plan and to this end I am pleased to report that our Tristel Jet product for hard surface disinfection has also been approved by the regulatory body. We have now entered the administrative licence process for this product. Our Wipes System is also in the process of being presented for regulatory approval."

Β 

Tristel plc

Paul Swinney, Chief Executive

Tel: 01638 721 500

finnCap

Geoff Nash / Charlotte Stranner (Corporate Finance)

Simon Starr (broking)

Tel: 020 7600 1658

Walbrook PR

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07866 384 707

paul.cornelius@walbrookir.com

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCSFDSMEFFSEII
Date   Source Headline
17th Jun 20267:00 amRNSAppointment of CEO
16th Jun 202612:00 pmRNSHolding(s) in Company
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights
15th May 20257:00 amRNSCFO succession planning
12th May 20257:00 amRNSFDA clearance for Tristel OPH

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.